Summary

U.S. Home Infusion Therapy Market Summary

The U.S. home infusion therapy market size was estimated at USD 20.42 billion in 2024 and is expected to reach USD 39.96 billion by 2033, growing at a CAGR of 7.78% from 2025 to 2033. The increasing elderly population susceptible to severe health conditions is a significant factor driving market growth.

In addition, the rising prevalence of disorders such as cancer, diabetes, chronic pain, and gastrointestinal diseases is anticipated to further stimulate growth in the U.S. market. Home infusion therapy provides various advantages for patients, including cost-effectiveness, improved health outcomes, enhanced convenience, and elevated safety standards.

Aging is one of the leading risk factors for developing infections and associated complications. Thus, the rapidly aging U.S. population is anticipated to drive market growth. For instance, according to the Population Reference Bureau, the number of people aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050. Increasing patients’ preference for home therapy is also driving the market growth. Home healthcare supports the daily life activities of patients and provides better access to skilled medical care. As compared to hospital treatment, home infusion therapy is cost-effective since it eliminates hospital stays and ultimately saves the patient’s money. Home infusion therapy also allows the patient to maintain higher safety due to less risk of hospital-acquired infections at home. This augments the demand for home treatment, thereby driving the market growth.

This country’s high prevalence of cancer, diabetes, and other chronic diseases propels market growth further. According to the American Cancer Society, nearly 1.9 million new cancer cases were expected to be diagnosed with 609,360 cancer deaths in 2022. The prevalence of diabetes in the U.S is also quite significant, which can be attributed to negative lifestyle choices and a stressful work environment. Moreover, there has been a constant surge in the prevalence of cardiovascular and chronic respiratory diseases in the country. In addition, factors such as a growing geriatric population and increasing volume of surgical procedures are expected to propel the country’s demand for intravenous infusion pumps in the forecast period.

Moreover, the government is expected to introduce stricter regulations and adopt new standards for safer & efficient practices. This progress is being achieved by improving national standards of care via the Infusion Therapy Standards of Practice and the Policies and Procedures for Infusion Nursing, along with upgrading policies of individual care providers. Moreover, new product launches and FDA approvals significantly contribute to market growth. For instance, in April 2024, Baxter received U.S. FDA clearance for its Novum IQ large volume infusion pump and Dose IQ safety software. This advancement enhances connected and intelligent infusion therapy, improving patient safety and care efficiency.
U.S. Home Infusion Therapy Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. home infusion therapy market report based on Type, and application.
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Product
o Infusion PumpsIntravenous Sets
o Elastomeric
o Electromechanical
o Gravity
o Others
o Intravenous Sets
o IV Cannulas
o Needleless Connectors
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Anti-infective
• Endocrinology
o Diabetes
o Others
• Hydration Therapy
o Athletes
o Others
• Chemotherapy
• Enteral Nutrition
• Parenteral Nutrition
• Specialty Pharmaceuticals
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Application Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. U.S. Home Infusion Therapy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of chronic diseases and growing geriatric population
3.2.1.2. Technological advancements
3.2.1.3. Growing incidence of hospital-acquired infections
3.2.2. Market restraint analysis
3.2.2.1. Presence of complicated reimbursement framework and reimbursement cuts
3.3. U.S. Home Infusion Therapy Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.2.4. Environmental Landscape
3.3.2.5. Legal Landscape
3.3.2.6. Social Landscape
Chapter 4. U.S. Home Infusion Therapy Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Home Infusion Therapy Market Type Movement Analysis
4.3. U.S. Home Infusion Therapy Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Product
4.4.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.4.2. Infusion pumps
4.4.2.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.4.2.2. Elastomeric
4.4.2.2.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.4.2.3. Electromechanical
4.4.2.3.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.4.2.4. Gravity
4.4.2.4.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.4.2.5. Others
4.4.2.5.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.4.3. Intravenous Sets
4.4.3.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.4.4. IV Cannulas
4.4.4.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.4.5. Needleless Connectors
4.4.5.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.5. Services
4.5.1. Market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 5. U.S. Home Infusion Therapy Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Home Infusion Therapy Market Application Movement Analysis
5.3. U.S. Home Infusion Therapy Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Anti-Infective
5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Endocrinology
5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.5.2. Diabetes
5.5.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.5.3. Others
5.5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Hydration Therapy
5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.6.2. Athletes
5.6.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.6.3. Others
5.6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Chemotherapy
5.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.8. Enteral Nutrition
5.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.9. Parenteral Nutrition
5.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.10. Specialty Pharmaceuticals
5.10.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.11. Others
5.11.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Competitive Landscape
6.1. Company/Competition Categorization
6.2. Strategy Mapping
6.3. Company Market Position Analysis, 2024
6.4. Company Profiles/Listing
6.4.1. B. Braun Melsungen
6.4.1.1. Company overview
6.4.1.2. Financial performance
6.4.1.3. Product benchmarking
6.4.1.4. Strategic initiatives
6.4.2. Baxter International
6.4.2.1. Company overview
6.4.2.2. Financial performance
6.4.2.3. Product benchmarking
6.4.2.4. Strategic initiatives
6.4.3. Caesarea Medical Electronics Ltd.
6.4.3.1. Company overview
6.4.3.2. Financial performance
6.4.3.3. Product benchmarking
6.4.3.4. Strategic initiatives
6.4.4. CareFusion
6.4.4.1. Company overview
6.4.4.2. Financial performance
6.4.4.3. Product benchmarking
6.4.4.4. Strategic initiatives
6.4.5. Fresenius Kabi
6.4.5.1. Company overview
6.4.5.2. Financial performance
6.4.5.3. Product benchmarking
6.4.5.4. Strategic initiatives
6.4.6. ICU Medical
6.4.6.1. Company overview
6.4.6.2. Financial performance
6.4.6.3. Product benchmarking
6.4.6.4. Strategic initiatives
6.4.7. JMS CO., LTD.
6.4.7.1. Company overview
6.4.7.2. Financial performance
6.4.7.3. Product benchmarking
6.4.7.4. Strategic initiatives
6.4.8. Smiths Medical, Inc.
6.4.8.1. Company overview
6.4.8.2. Financial performance
6.4.8.3. Product benchmarking
6.4.8.4. Strategic initiatives
6.4.9. Terumo Corporation
6.4.9.1. Company overview
6.4.9.2. Financial performance
6.4.9.3. Product benchmarking
6.4.9.4. Strategic initiatives
6.4.10. Coram LLC
6.4.10.1. Company overview
6.4.10.2. Financial performance
6.4.10.3. Product benchmarking
6.4.10.4. Strategic initiatives
6.4.11. Option Care Enterprises, Inc.
6.4.11.1. Company overview
6.4.11.2. Financial performance
6.4.11.3. Product benchmarking
6.4.11.4. Strategic initiatives
6.4.12. BioScrip, Inc.
6.4.12.1. Company overview
6.4.12.2. Financial performance
6.4.12.3. Product benchmarking
6.4.12.4. Strategic initiatives
6.4.13. BriovaRx Infusion Services
6.4.13.1. Company overview
6.4.13.2. Financial performance
6.4.13.3. Product benchmarking
6.4.13.4. Strategic initiatives
6.4.14. Paragon Healthcare
6.4.14.1. Company overview
6.4.14.2. Financial performance
6.4.14.3. Product benchmarking
6.4.14.4. Strategic initiatives